鼻咽癌放化疗局部失败的相关因素分析

王茂鑫; 陈贤明; 赵敏; 陈辉; 张贤

doi:10.13201/j.issn.1001-1781.2013.21.010

鼻咽癌放化疗局部失败的相关因素分析

- 南京军区福州总医院耳鼻咽喉-头颈外科(福州, 350025)

详细信息

通讯作者: 王茂鑫,E-mail:entmao@126.com

中图分类号: R739.63

收稿日期: 2013-07-25

Risk factors analysis of local failure following radiotherapy and chemotherapy to nasopharyngeal carcinoma

- Department of Otolaryngology-Head and Neck Surgery, Fuzhou General Hospital of PLA, Fuzhou, 350025, China

More Information

Corresponding author: WANG Maoxin, E-mail: entmao@126.com

Received Date: 25 July 2013

摘要

摘要: 目的:探讨鼻咽癌放化疗后局部失败(残留或复发)的相关影响因素。方法:对308例鼻咽部原发癌患者的临床病理资料进行回顾分析。选择性别、年龄、T分级、N分级、原发癌病理类型、有无颈淋巴结转移、颈转移淋巴结大小、颈淋巴结转移侧数、颈淋巴结转移累及区域、放疗方法、有无同步化疗等临床病理因素,用χ²检验和Logistic回归进行单因素和多因素分析,并用Kaplan-Meier法对残留和复发患者进行生存分析。结果:在308例头颈部原发鳞状细胞癌患者中,93例(30.2%)发生原发灶和颈部的残留或复发。单因素分析显示, T分级(P<0.01)、N分级(P<0.01)、有无颈淋巴结转移(P<0.05)、颈转移淋巴结大小(P<0.05)、颈淋巴结转移侧数(P<0.01)与残留或复发有关。多因素分析结果表明,仅T分级与残留或复发明显相关。用Kaplan-Meier法进行生存分析显示71例残留或复发患者再次治疗的1年、3年、5年生存率分别为77.2%、40.4%、22.4%。结论:原发癌T分级是鼻咽癌治疗局部失败的决定性因素。而有无颈淋巴结转移、原发癌N分级、颈淋巴结转移侧数、颈淋巴结大小是影响因素和T分级的协同因素,但不是导致残留和复发的的初始和根本因素。鼻咽癌侵犯骨时易导致治疗失败。治疗失败者经再次治疗可以提高生存率。
- 鼻咽癌 /
- 放射治疗 /
- 化学治疗 /
- 残留 /
- 复发 /
- 因素分析 /
- 统计学
Abstract: Objective: To analyse the risk factors involved in local failure following radiotherapy and chemotherapy to nasopharyngeal carcinoma.Method: A retrospective analysis was carried out to review the histopathological data from 308 NPC patients who recieved medical treatment between 2004 and 2006. The incidence and the risk factor for local treatment failure were evaluated in a model that included the following factors: sex, age, T and N staging, histological grade of primary tumor, presence of cervical lymph node metastasis, size and laterals of positive neck nodes, levels involved, ways of radiation and condition of concurrent chemotherapy. Univariate χ² test and multivariate stepwise logistic regression model were used for the analysis.Statistical analysis of survival of patients with local residues and recurrence was performed using Kaplan-Meier method.Result: Ninty-three cases(30.2%) presented local residues and recurrence in 308 patients of nasopharyngeal carcinomas. In the univariate analysis, it was confirmed that the following variables correlated to local failure, i.e., T staging(P<0.01), N staging(P<0.01), presence of cervical lymph node metastasis(P<0.05), size and laterals of positive neck nodes(P<0.05, respectively). In the multivariate analysis, the most ignificant risk factors for local failure were the T staging only. Kaplan-Meier analysis showed that overall survival rates of 71 NPC patients with local residues and recurrence who received re-treatment were 77.2% at 1 year, 40.4% at 3 years, 22.4% at 5 years, respectively.Conclusion: T staging is the key risk factors in determining the development of local failure following radiotherapy or chemotherapy in NPC patients. Patients with primary tumor infiltrating bone have the higher risk of developing local residues and recurrence. Retreatment to the patients suffering from local failure can imrove survival rates.
- nasopharyngeal carcinoma /
- radiotherapy /
- chemotherapy /
- residue /
- recurrence /
- factor analysis /
- statistical

HTML全文

参考文献(16)

[1]	李先明,李子煌,吴超权,等.鼻咽癌根治性放疗的预后分析[J].中华肿瘤防治杂志,2009, 16(15):1173-1177.
[2]	XU L,PAN J,WU J,et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma:significance of intensive neoadjuvant chemotherapy and radiation break[J].Radiother Oncol,2010, 96:94-99.
[3]	GOKCE T,UNLU I,AKCAY C. Evaluation of overall survival of nasopharyngeal carcinoma patients treated in ten years at a single institution[J]. J BUON, 2010, 15:36-42.
[4]	LEE A W,TUNG S Y,CHUA D T,et al. Randomized trial of radiotherapy plus concurrent adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst,2010,102:1188-1198.
[5]	GAO F, JOSEPH W, HWEE B,et al. Quality-of-life-adjusted survival analysis of concurrent chemoradiotherapy for locally advanced(nonmetastatic) nasopharyngeal cancer[J]. Int J Radiation Oncol Biol Phys, 2010,78:454-460.
[6]	邱素芳,林少俊,陆军,等. 140例局部残留和复发鼻咽癌患者三维适形放疗的疗效分析[J]. 中国癌症杂志, 2011, 21(9):701-707.
[7]	LOONG H, MA B, CHAN A. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer[J]. Hematol Oncol Clin North Am, 2008, 22:1267-1278.
[8]	HAN F, ZHAO C, HUANG S, et al. Long-term Outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy[J].Clin Oncol(R Coll Radiol),2012,24:569-576.
[9]	马骏,麦海强,莫浩元,等.鼻咽癌放射治疗失败原因分析[J].癌症,2000,19(11):1016-1018.
[10]	易俊林, 高黎, 黄晓东,等. 鼻咽癌放射治疗的失败模式[J]. 中华放射肿瘤学杂志, 2004,13(3):145-148.
[11]	PALAZI M, ORLANDI E, BOSSI P, et al. Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy:an update of the milan experince[J]. Int J Radiation Oncology Biol Phys, 2009, 74:774-780.
[12]	林灿峰, 李德锐,陈志坚, 等.同期化疗对Ⅲ期鼻咽癌放疗患者预后影响的回顾性分析[J]. 中华肿瘤防治杂志, 2011, 18(8):597-601.
[13]	阿依恒·曲库尔汗,尼力帕尔·阿木力,亚力坤·亚生,等.Genistein对人鼻咽癌细胞系CNE抑制增殖和促进凋亡的作用及机制探讨[J].临床耳鼻咽喉头颈外科杂志, 2011,25(18):843-847.
[14]	MEHRA R,COHEN R,BURTNESS B. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck[J]. Clin Adv Hematol Oncol, 2008,6:742-750.
[15]	BONNER J,HARARI P,GIRALT J, et al. Radiotherapy plus cetuximab treatment of locoregionally advanced head and neck cancer:one of phase Ⅲ study clinical trials's 5-year survival data and the relationship between cetuximab-induced rash and survival[J].Lancet Oncol,2010,11:21-28.
[16]	王建玲,周慧芳,杨东.鼻咽癌治疗新进展[J].临床耳鼻咽喉头颈外科杂志,2011,25(21):1005-1008.